TY - JOUR
T1 - Spectrum of Clinical and Imaging Features of Children with GFAP Astrocytopathy
AU - Sommer, Simon
AU - Panzer, Andreas
AU - Bertolini, Annikki
AU - Cleaveland, Robert
AU - Jain, Vivek
AU - Kapanci, Tugba
AU - Derichs, Ute
AU - Geis, Tobias
AU - Neu, Axel
AU - Löhr-Nilles, Christa
AU - Aeschimann-Huhn, Rahel
AU - Flotats-Bastardas, Marina
AU - Deiva, Kumaran
AU - Armangue, Thais
AU - Olivé-Cirera, Gemma
AU - Kannoth, Sudheeran
AU - Koy, Anne
AU - Meirson, Hadas
AU - Fattal-Valevski, Aviva
AU - Ganelin-Cohen, Esther
AU - Losch, Heike
AU - Horne, Annacarin
AU - Wickström, Ronny
AU - Dargvainiene, Justina
AU - Leypoldt, Frank
AU - Rostasy, Kevin
N1 - Publisher Copyright:
© 2024 American Academy of Neurology.
PY - 2024/11/20
Y1 - 2024/11/20
N2 - Background and ObjectivesGlial fibrillary acidic protein (GFAP) antibodies (abs) have been described primarily in adults with a spectrum of autoimmune-mediated diseases. In children, data on clinical and neuroradiologic features of children with autoimmune GFAP astrocytopathy are limited. The aim of this study was to describe the clinical and radiologic features in children with GFAP-ab-associated diseases.MethodsWe retrospectively recruited children from 13 clinical centers between 2020 and 2023 who (1) tested positive for GFAP-ab in serum and/or CSF and (2) of whom a complete clinical and MRI data set was available.ResultsWe identified and included 15 children (5 girls, 10 boys). The median age at onset was 9.9 years (range: 2-16 years). All children presented with features of AE or meningitis, acute cerebellitis, or transverse myelitis. CSF pleocytosis was common (13/15, median 245 cells/L), and 13 (87%) of 15 harbored GFAP-abs in their CSF, 8 (53%) of whom did not have detectable GFAP-abs in their serum. MRI was abnormal in 15 (100%) of 15 children: Specific patterns included confluent lesions in the pons or caudate nucleus (11/15; 73%), peri-aqueductal regions (13/15; 87%), and spinal cord (6/10; 60%). 12 children had a favorable outcome (mRS score of </= 1). Two patients died in the acute phase or during follow-up.DiscussionGFAP-ab-associated diseases encompass a wide spectrum of clinical presentation associated with a particular set of MRI features clearly distinct to other antibody-mediated diseases or MOGAD. We recommend that testing for GFAP-abs in serum and CSF be included in the workup of children with AE, particularly if brainstem involvement occurs.
AB - Background and ObjectivesGlial fibrillary acidic protein (GFAP) antibodies (abs) have been described primarily in adults with a spectrum of autoimmune-mediated diseases. In children, data on clinical and neuroradiologic features of children with autoimmune GFAP astrocytopathy are limited. The aim of this study was to describe the clinical and radiologic features in children with GFAP-ab-associated diseases.MethodsWe retrospectively recruited children from 13 clinical centers between 2020 and 2023 who (1) tested positive for GFAP-ab in serum and/or CSF and (2) of whom a complete clinical and MRI data set was available.ResultsWe identified and included 15 children (5 girls, 10 boys). The median age at onset was 9.9 years (range: 2-16 years). All children presented with features of AE or meningitis, acute cerebellitis, or transverse myelitis. CSF pleocytosis was common (13/15, median 245 cells/L), and 13 (87%) of 15 harbored GFAP-abs in their CSF, 8 (53%) of whom did not have detectable GFAP-abs in their serum. MRI was abnormal in 15 (100%) of 15 children: Specific patterns included confluent lesions in the pons or caudate nucleus (11/15; 73%), peri-aqueductal regions (13/15; 87%), and spinal cord (6/10; 60%). 12 children had a favorable outcome (mRS score of </= 1). Two patients died in the acute phase or during follow-up.DiscussionGFAP-ab-associated diseases encompass a wide spectrum of clinical presentation associated with a particular set of MRI features clearly distinct to other antibody-mediated diseases or MOGAD. We recommend that testing for GFAP-abs in serum and CSF be included in the workup of children with AE, particularly if brainstem involvement occurs.
UR - http://www.scopus.com/inward/record.url?scp=85210340290&partnerID=8YFLogxK
U2 - 10.1212/NXI.0000000000200327
DO - 10.1212/NXI.0000000000200327
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39566024
AN - SCOPUS:85210340290
SN - 2332-7812
VL - 12
JO - Neurology: Neuroimmunology and NeuroInflammation
JF - Neurology: Neuroimmunology and NeuroInflammation
IS - 1
M1 - e200327
ER -